Alió Jorge L, Soria Felipe, Abbouda Alessandro, Peña-García Pablo
From Vissum Instituto Oftalmologico de Alicante (Alió, Soria, Abbouda) and the Division of Ophthalmology (Alió, Peña-García), Universidad Miguel Hernández, Alicante, Spain.
From Vissum Instituto Oftalmologico de Alicante (Alió, Soria, Abbouda) and the Division of Ophthalmology (Alió, Peña-García), Universidad Miguel Hernández, Alicante, Spain.
J Cataract Refract Surg. 2015 Jan;41(1):33-40. doi: 10.1016/j.jcrs.2014.08.029. Epub 2014 Nov 20.
To evaluate the long-term outcomes of laser in situ keratomileusis (LASIK) for high myopia with or without astigmatism.
Vissum Instituto Oftalmologico de Alicante and Miguel Hernandez University, Alicante, Spain.
Retrospective-prospective case series.
Laser in situ keratomileusis was performed using the Visx 20/20 excimer laser. The minimum follow-up was 15 years. The main outcome measures were uncorrected (UDVA) and corrected (CDVA) distance visual acuities, manifest refraction, and corneal topography.
This study included 40 patients (40 eyes) with a mean age of 51.08 years ± 6.67 (SD) (range 41 to 60 years) with high myopia (-6.00 to -18.00 diopters [D]). At 15 years, the safety index was 1.23 and the efficacy index, 0.95. During the follow-up, a significant increase in the dioptric power of all keratometric variables was detected (P≤.028, Friedman test), the most notable increase occurring between 3 months and 1 year (P≤.005). At 15 years, 46.15% of the eyes were within ±1.00 D of the attempted spherical equivalent and 64.10% were within ±2.00 D. The UDVA at 15 years was 20/25 or better in 43.59% of eyes and 20/40 or better in 64.10% of eyes. The postoperative CDVA was significantly better than preoperatively (P<.001). The postoperative complications were minor except in 1 eye in which ectasia occurred.
Laser in situ keratomileusis for high myopia was safe over the long term. However, significant myopic regression with time was detected. Low preoperative pachymetry and low residual stromal bed were predictors of keratometric regression.
No author has a financial or proprietary interest in any material or method mentioned.
评估准分子原位角膜磨镶术(LASIK)治疗伴有或不伴有散光的高度近视的长期效果。
西班牙阿利坎特市的维苏姆眼科研究所和米格尔·埃尔南德斯大学。
回顾性-前瞻性病例系列研究。
使用威视20/20准分子激光进行准分子原位角膜磨镶术。最短随访时间为15年。主要观察指标为未矫正远视力(UDVA)、矫正远视力(CDVA)、显验光和角膜地形图。
本研究纳入40例患者(40只眼),平均年龄51.08岁±6.67(标准差)(范围41至60岁),为高度近视(-6.00至-18.00屈光度[D])。15年后,安全指数为1.23,疗效指数为0.95。随访期间,所有角膜测量变量的屈光度均有显著增加(Friedman检验,P≤.028),最显著的增加发生在3个月至1年之间(P≤.005)。15年后,46.15%的眼睛球镜等效度在预期值±1.00 D范围内,64.10%的眼睛在±2.00 D范围内。15年后,43.59%的眼睛UDVA为20/25或更好,64.10%的眼睛为20/40或更好。术后CDVA显著优于术前(P<.001)。除1只眼发生角膜扩张外,术后并发症均较轻微。
准分子原位角膜磨镶术治疗高度近视长期安全。然而,随时间推移出现了显著的近视回退。术前角膜厚度低和剩余基质床薄是角膜测量回退的预测因素。
没有作者对文中提及的任何材料或方法拥有财务或专利权益。